O	0	5	Phase
O	6	8	II
O	9	19	randomized
O	20	25	study
O	26	28	of
B-intervention	29	34	whole
I-intervention	34	35	-
I-intervention	35	40	brain
I-intervention	41	50	radiation
I-intervention	51	58	therapy
I-intervention	59	63	with
I-intervention	64	66	or
I-intervention	67	74	without
I-intervention	75	85	concurrent
I-intervention	86	98	temozolomide
O	99	102	for
O	103	108	brain
O	109	119	metastases
O	120	124	from
O	125	131	breast
O	132	138	cancer
O	138	139	.

O	140	142	To
O	143	150	improve
O	151	154	the
O	155	166	therapeutic
O	167	172	index
O	173	175	of
O	176	181	whole
O	181	182	-
O	182	187	brain
O	188	197	radiation
O	198	205	therapy
O	206	207	(
O	207	211	WBRT
O	211	212	)
O	213	215	in
O	216	219	the
O	220	229	treatment
O	230	232	of
O	233	238	brain
O	239	249	metastases
O	250	251	(
O	251	253	BM
O	253	254	)
O	255	259	from
O	260	266	breast
O	267	273	cancer
O	273	274	,
O	275	277	we
O	278	290	investigated
O	291	294	the
O	295	303	efficacy
O	304	307	and
O	308	314	safety
O	315	317	of
O	318	322	WBRT
O	323	331	combined
O	332	336	with
O	337	349	temozolomide
O	350	351	(
O	351	354	TMZ
O	354	355	)
O	356	358	in
O	359	363	this
O	364	374	population
O	374	375	.

O	376	380	This
O	381	386	phase
O	387	389	II
O	390	401	multicenter
O	402	413	prospective
O	414	424	randomized
O	425	430	study
O	431	439	included
B-eligibility	440	448	patients
I-eligibility	449	453	with
I-eligibility	454	459	newly
I-eligibility	460	469	diagnosed
I-eligibility	470	486	intraparenchymal
I-eligibility	487	490	BMs
I-eligibility	491	495	from
I-eligibility	496	502	breast
I-eligibility	503	509	cancer
I-eligibility	509	510	,
I-eligibility	511	521	unsuitable
I-eligibility	522	525	for
I-eligibility	526	533	surgery
I-eligibility	534	536	or
I-eligibility	537	549	radiosurgery
O	549	550	.

O	551	554	All
O	555	563	patients
O	564	572	received
O	573	582	conformal
O	583	587	WBRT
O	588	589	(
O	589	590	3
O	591	593	Gy
O	594	595	×
O	596	598	10
O	598	599	-
O	599	601	30
O	602	604	Gy
O	604	605	)
O	605	606	,
O	607	611	with
O	612	614	or
O	615	622	without
O	623	634	concomitant
O	635	638	TMZ
O	639	651	administered
O	652	654	at
O	655	656	a
O	657	663	dosage
O	664	666	of
O	667	669	75
O	670	672	mg
O	672	673	/
O	673	674	m
O	674	675	(
O	675	676	2
O	676	677	)
O	677	678	/
O	678	681	day
O	682	688	during
O	689	692	the
O	693	704	irradiation
O	705	711	period
O	711	712	.

O	713	716	The
O	717	724	primary
O	725	728	end
O	729	734	point
O	735	738	was
B-outcome-Measure	739	748	objective
I-outcome-Measure	749	757	response
I-outcome-Measure	758	762	rate
I-outcome-Measure	763	764	(
I-outcome-Measure	764	767	ORR
I-outcome-Measure	767	768	)
O	769	770	6
O	771	776	weeks
O	777	782	after
O	783	786	the
O	787	790	end
O	791	793	of
O	794	803	treatment
O	803	804	,
O	805	812	defined
O	813	815	as
O	816	817	a
O	818	825	partial
O	826	828	or
O	829	837	complete
O	838	846	response
O	847	849	on
O	850	860	systematic
O	861	866	brain
O	867	870	MRI
O	871	872	(
O	872	880	modified
O	881	884	WHO
O	885	893	criteria
O	893	894	)
O	894	895	.

O	896	905	Secondary
O	906	909	end
O	910	916	points
O	917	921	were
B-outcome-Measure	922	933	progression
I-outcome-Measure	933	934	-
I-outcome-Measure	934	938	free
I-outcome-Measure	939	947	survival
I-outcome-Measure	948	949	(
I-outcome-Measure	949	952	PFS
I-outcome-Measure	952	953	)
O	954	957	and
B-outcome-Measure	958	965	overall
I-outcome-Measure	966	974	survival
I-outcome-Measure	975	976	(
I-outcome-Measure	976	978	OS
I-outcome-Measure	978	979	)
O	979	980	,
B-outcome-Measure	981	991	neurologic
I-outcome-Measure	992	1000	symptoms
O	1000	1001	,
O	1002	1005	and
B-outcome-Measure	1006	1018	tolerability
O	1018	1019	.

O	1020	1027	Between
O	1028	1036	February
O	1037	1041	2008
O	1042	1045	and
O	1046	1054	November
O	1055	1059	2010
O	1059	1060	,
B-total-participants	1061	1064	100
O	1065	1073	patients
O	1074	1078	were
O	1079	1087	enrolled
O	1088	1090	in
O	1091	1094	the
O	1095	1100	study
O	1101	1102	(
B-intervention-participants	1102	1104	50
O	1105	1107	in
O	1108	1111	the
O	1112	1116	WBRT
O	1117	1118	+
O	1119	1122	TMZ
O	1123	1126	arm
O	1126	1127	,
B-control-participants	1128	1130	50
O	1131	1133	in
O	1134	1137	the
B-control	1138	1142	WBRT
O	1143	1146	arm
O	1146	1147	)
O	1147	1148	.

O	1149	1155	Median
O	1156	1159	age
O	1160	1163	was
B-age	1164	1166	55
I-age	1167	1172	years
O	1173	1174	(
O	1174	1176	29
O	1176	1177	-
O	1177	1179	79
O	1179	1180	)
O	1180	1181	.

O	1182	1188	Median
O	1189	1195	follow
O	1195	1196	-
O	1196	1198	up
O	1199	1202	was
O	1203	1204	9
O	1204	1205	.
O	1205	1206	4
O	1207	1213	months
O	1214	1215	[
O	1215	1216	1
O	1216	1217	.
O	1217	1218	0
O	1218	1219	-
O	1219	1221	68
O	1221	1222	.
O	1222	1223	1
O	1223	1224	]
O	1224	1225	.

B-outcome	1226	1230	ORRs
I-outcome	1231	1233	at
I-outcome	1234	1235	6
I-outcome	1236	1241	weeks
O	1242	1246	were
B-cv-bin-percent	1247	1249	36
I-cv-bin-percent	1249	1250	%
O	1251	1253	in
O	1254	1257	the
O	1258	1262	WBRT
O	1263	1266	arm
O	1267	1270	and
B-iv-bin-percent	1271	1273	30
I-iv-bin-percent	1273	1274	%
O	1275	1277	in
O	1278	1281	the
O	1282	1286	WBRT
O	1287	1288	+
O	1289	1292	TMZ
O	1293	1296	arm
O	1297	1298	(
O	1298	1300	NS
O	1300	1301	)
O	1301	1302	.

O	1303	1305	In
O	1306	1309	the
O	1310	1314	WBRT
O	1315	1318	arm
O	1318	1319	,
B-outcome	1320	1326	median
I-outcome	1327	1330	PFS
O	1331	1334	was
B-cv-cont-median	1335	1336	7
I-cv-cont-median	1336	1337	.
I-cv-cont-median	1337	1338	4
I-cv-cont-median	1339	1345	months
O	1346	1349	and
B-outcome	1350	1356	median
I-outcome	1357	1359	OS
O	1360	1363	was
B-cv-cont-median	1364	1366	11
I-cv-cont-median	1366	1367	.
I-cv-cont-median	1367	1368	1
I-cv-cont-median	1369	1375	months
O	1375	1376	.

O	1377	1379	In
O	1380	1383	the
O	1384	1388	WBRT
O	1389	1390	+
O	1391	1394	TMZ
O	1395	1398	arm
O	1398	1399	,
B-outcome	1400	1406	median
I-outcome	1407	1410	PFS
O	1411	1414	was
B-iv-cont-median	1415	1416	6
I-iv-cont-median	1416	1417	.
I-iv-cont-median	1417	1418	9
I-iv-cont-median	1419	1425	months
O	1426	1429	and
B-outcome	1430	1436	median
I-outcome	1437	1439	OS
O	1440	1443	was
B-iv-cont-median	1444	1445	9
I-iv-cont-median	1445	1446	.
I-iv-cont-median	1446	1447	4
I-iv-cont-median	1448	1454	months
O	1454	1455	.

O	1456	1465	Treatment
O	1466	1469	was
O	1470	1474	well
O	1475	1484	tolerated
O	1485	1487	in
O	1488	1492	this
O	1493	1496	arm
O	1496	1497	:
O	1498	1501	the
O	1502	1506	most
O	1507	1513	common
B-outcome	1514	1515	≥
I-outcome	1515	1520	grade
I-outcome	1521	1522	2
I-outcome	1523	1528	acute
I-outcome	1529	1537	toxicity
O	1538	1541	was
B-outcome	1542	1552	reversible
I-outcome	1553	1564	lymphopenia
O	1564	1565	.

O	1566	1570	WBRT
O	1571	1579	combined
O	1580	1584	with
O	1585	1588	TMZ
O	1589	1592	did
O	1593	1596	not
O	1597	1610	significantly
O	1611	1618	improve
O	1619	1624	local
O	1625	1632	control
O	1633	1636	and
O	1637	1645	survival
O	1646	1648	in
O	1649	1657	patients
O	1658	1662	with
O	1663	1666	BMs
O	1667	1671	from
O	1672	1678	breast
O	1679	1685	cancer
O	1685	1686	.

O	1687	1701	CLINICALTRIALS
O	1701	1702	.
O	1702	1705	GOV
O	1705	1706	:
O	1706	1717	NCT00875355
O	1717	1718	.
